Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SMITHKLINE BEECHAM FAMVIR SHINGLES TREATMENT LABELED FOR T.I.D. DOSING

Executive Summary

SMITHKLINE BEECHAM FAMVIR SHINGLES TREATMENT LABELED FOR T.I.D. DOSING, less frequent than labeled dosing of the only other approved shingles (varicella zoster virus) treatment, Burroughs Wellcome's Zovirax (acyclovir), FDA cleared Farnvir (famciclovir) for marketing June 29, Recommended Farnvir dosing is one 500 mg tablet every eight hours for seven days, approved labeling states, while Zovirax labeling recommends 800 mg every four hours five times daily for 7-10 days,

Latest Headlines
See All
UsernamePublicRestriction

Register

PS024718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel